Alternatively Speaking is a podcast series that delves deep into alternative and emerging industries that are primed to drive the future global economy. Each season, our hosts will interview experts and pioneers in specific cutting-edge industries as we aim to get a better understanding of what the future holds.
Site
RSS
Apple
Recent rankings
Latest chart positions across Apple Podcasts and Spotify rankings.
Shared links between episodes and podcasts
Links found in episode descriptions and other podcasts that share them.
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
Today, we welcome our first-ever guest, Jamie Justice, Executive Vice President of the Health Domain at XPRIZE Foundation and Adjunct Professor in Internal Medicine Section on Gerontology and Geriatric Medicine, and Sticht Center on Healthy Aging and Alzheimer’s Prevention at Wake Forest University School of Medicine (WFUSM).
Jamie is dedicated to Geroscience research that advances the hypothesis that by targeting the basic biology of aging the incidence of multiple age-related diseases can be delayed or prevented. Her training background at University of Colorado Boulder and WFUSM allowed her to lead translational research and clinical trials networks to test the Geroscience hypothesis in humans. At WFUSM, Jamie was director of the Biogerontology Lab, and co-leader of the Integrative Biology Core (IBC) of the WF Claude D. Pepper Older Americans Independence Center (OAIC) and was a Principal Investigator of the National Institute of Aging-supported Geroscience Education and Training Network, an engaged member of the Translational Geroscience Network, Gerontological Society of America’s ESPO scientific section officer and executive committee member from 2018-2021.
Jamie is the recipient of the Jarrahi Research Scholars Fund in Geroscience Innovation, the 2022 Vincent Cristofalo Rising Star in Aging Research, and the 2022 NIA Nathan W Shock Awardee. In her new role as EVP of Health Domain she will lead international networks to drive innovative solutions to improve human health and aging that is affordable and accessible to all.
Podcast Highlights:
Introduction & XPRIZE Foundation Origins (00:00 - 02:29): Overview of the longevity industry, the impact of the Ansari XPRIZE on private space travel, and XPRIZE’s influence on companies like SpaceX.
Jamie Justice’s Background & Passion for Research (02:30 - 06:14): Jamie’s journey into gerontology, early research experiences with older adults, and her focus on empathy and the human aspect of aging.
Exploring Aging & Longevity (06:15 - 10:21): Discussion on the fundamental questions of aging, how different interventions (lifestyle, supplements, drugs) impact human health and longevity.
Translating Aging Research into Practice (10:22 - 13:10): Jamie’s work at Wake Forest, ongoing efforts to apply aging research in real-world settings, and the philosophical aspects of aging—living fully versus focusing on death.
Healthspan vs. Lifespan & Longevity Goals (13:11 - 20:43): Exploring the concept of the ‘longevity dividend,’ aligning biological health with extended life, and the strategies to improve healthspan by optimizing current biology.
XPRIZE HealthSPAN Award & Future of Aging Research (20:44 - 28:28): Introduction to the XPRIZE HealthSPAN Award program, the bold scientific goals it supports, challenges in aging research, and the collaborative efforts to advance the field.
Social Media:
X: @j_n_justice
LinkedIn: https://www.linkedin.com/in/jamie-justice-ph-d-6b933146/
Other Links/Mentions:
https://www.xprize.org/
https://www.xprize.org/prizes/healthspan
Show Credits:
This episode was hosted by Anne Donohoe of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels:
X: @KCSAPodcastLabs
Instagram: @KCSAPodcastLabs
LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/
Alternatively Speaking – S1 Introduction to Longevity
Tuesday, September 3, 2024 • Duration 04:46
Welcome to Alternatively Speaking, a new podcast series by KCSA Podcast Labs, the team behind the Green Rush Podcast.
Join us on a captivating journey through the complex and fascinating world of longevity in our single-season, 10-episode series. Each week, we dive deep into the advancements and challenges surrounding the pursuit of longer, healthier lives. From exploring the scientific foundations of aging and the latest technologies aimed at combating it to examining the economic implications and who stands to benefit financially, our conversations provide a comprehensive look at this rapidly evolving field.
For the first episode, our hosts Lewis Goldberg, Anne Donohoe, and Phil Carlson discuss what led them to start Alternatively Speaking, why the first series will focus on longevity, and the key experts lined up to enlighten us on this new quest for information.
Our social channels can be found @KCSAPodcastLabs - or drop us an email at altspeaking@kcsa.com. Who else should we be speaking with? What other topics would you like us to explore? We want to hear from you!
Here’s to a long, healthy, productive life!
Show Credits:
This episode was hosted by Anne Donohoe of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:
X: @KCSAPodcastLabs
Instagram: @KCSAPodcastLabs
LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/
Longevity Reflections & AI Preview – S1 Finale
Tuesday, October 29, 2024 • Duration 38:25
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
For our final episode of the season, hosts Lewis Goldberg, Phil Carlson, and Anne Donohoe reflect on their journey through the world of longevity science and discuss key learnings from their conversations with industry leaders. The hosts also preview their upcoming season focused on artificial intelligence and its potential impact across various sectors.
Stay tuned for next season!
Links/Mentions/Resources:
Princeton Longevity Center: https://princetonlongevitycenter.com/
Fountain Life: https://www.fountainlife.com/
Dr. Matt Walker: https://www.sleepdiplomat.com/
HMNC Brain Health: https://www.hmnc-brainhealth.com/
Abundance360’s Platinum Conference: https://longevity.abundance360.com/
Show Credits:
This episode was hosted by Lewis Goldberg, Phil Carlson, and Anne Donohoe of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels:
X: @KCSAPodcastLabs
Instagram: @KCSAPodcastLabs
LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/
Dr. Peter Diamandis, Futurist of AI & Human Longevity
Tuesday, October 22, 2024 • Duration 47:20
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
Today, our host sat down with Dr. Peter Diamandis, a visionary at the forefront of the longevity revolution. Named by Fortune as one of the “World’s 50 Greatest Leaders,” Diamandis has started over 20 companies in the areas of longevity, space, venture capital, and education.
Diamandis is the founder & executive chairman of the XPRIZE Foundation, which leads the world in designing & operating large-scale incentive competitions. He is also the co-founder and vice-chairman of Human Longevity Inc., merging advanced genomic sequencing with AI to develop therapies aimed at slowing down or even reversing aging. Additionally, Diamandis co-founded Fountain Life with Tony Robbins, a unique concierge healthcare company dedicated to revolutionizing the healthcare industry. Diamandis is the creator of Abundance360, a year-round program for entrepreneurs, investors, and executives focused on leveraging technology to drive positive change and leave a legacy.
Diamandis is a New York Times Bestselling author of three books: Abundance – The Future Is Better Than You Think, BOLD – How to go Big, Create Wealth & Impact the World and The Future is Faster Than You Think. He is also the executive founder of Singularity University, a graduate-level Silicon Valley institution that counsels the world's leaders on exponentially growing technologies.
Podcast Highlights:
Introduction & Dr. Diamandis' Motivations (4:01): Discussion of Diamandis' reasons for focusing on longevity, including its potential as a gift to humanity and a major business opportunity.
Envisioning Extended Lifespans (6:55): Exploration of how life might change with significantly extended lifespans and Diamandis' personal perspective on living to 150 or beyond.
Ethical Considerations of Longevity (10:24): Addressing concerns about overpopulation and resource depletion, with Diamandis' optimistic view on technological solutions.
Breakthrough Technologies in Longevity (15:58): Overview of AI's potential role in understanding aging and discussion of the $101 million XPRIZE Healthspan.
Fountain Life and Preventative Diagnostics (23:25): Introduction to Fountain Life's comprehensive health assessment approach and statistics on early disease detection.
Personal Health Practices (35:56): Diamandis' approach to diet, exercise, and supplements, with emphasis on reducing sugar intake and increasing vegetable consumption.
Investment in Longevity Science (38:28): Advice for potential investors in the longevity space and discussion of challenges in biotech investments.
Singularity and AI (42:24): Explanation of Ray Kurzweil's concept of the “singularity” and Diamandis' perspective on the rapid advancement of AI.
Guest Social Media:
LinkedIn: https://www.linkedin.com/in/peterdiamandis/
X: @PeterDiamandis
Other Links/Mentions/Resources:
Peter Diamandis Website: https://www.diamandis.com/
Books by Peter Diamandis: https://www.diamandis.com/books
Human Longevity Inc.: https://www.humanlongevity.com/
XPRIZE Foundation: https://www.xprize.org/
Fountain Life: https://www.fountainlife.com/
Singularity University: https://su.org/
Abundance360: https://www.abundance360.com/summit
All affiliated companies and foundations: https://www.diamandis.com/companies
Show Credits:
This episode was hosted by Lewis Goldberg of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels:
X: @KCSAPodcastLabs
Instagram: @KCSAPodcastLabs
LinkedIn: https://www.linkedin.
Sebastian Brunemeier, Longevity Biotech, Life Extension & the Next Era of Medicine
Tuesday, October 15, 2024 • Duration 56:53
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
Today, our hosts engage in a fascinating discussion with Sebastian Brunemeier, a true powerhouse in the longevity and regenerative medicine space. Sebastian is a biotech venture capitalist and company builder with a laser focus on extending human health span. As the co-founder and general partner of Healthspan Capital and the CEO and founder of ImmuneAgeBio, Sebastian is at the forefront of immune system rejuvenation research.
Over the past five years, he has co-founded four longevity biotech companies with a combined equity value exceeding $600 million. Sebastian's background includes roles as co-founder and chief investment officer at Cambrian Biopharma, co-founder and COO of Samsara Therapeutics, and principal at Apollo Health Ventures, the world's first and largest aging-focused venture capital fund managing $200 million in assets.
Sebastian’s influence extends beyond his business ventures, serving as a trustee of the British Society for Research on Aging, a mentor at the New York Academy of Sciences, and as an advisor to numerous organizations, including VitaDAO, Equator Therapeutics, and even McKinsey and Company.
Podcast Highlights:
Introduction to Sebastian Brunemeier (00:11): Overview of Sebastian's background and his various roles in the longevity biotech space.
The Longevity Biotech Landscape (02:36): Discussion of Sebastian's journey into longevity science and his mission to bring capital and talent into the field.
Healthspan Capital and Investment Strategy (27:48): Insights into Healthspan Capital's approach to investing in longevity biotech companies.
The Global Demographic Aging Crisis (23:25): Exploration of the "silver tsunami" and how longevity science aims to address this global challenge.
Cutting-Edge Research in Longevity (39:54): Discussion of promising studies in the longevity space, including blood plasma research and stem cell therapies.
The Political and Social Movement of Longevity (45:00): Introduction to the concept of startup cities and the Prospera project as hubs for longevity research and development.
Personal Longevity Practices (53:35): Sebastian's insights on personal health protocols and cautionary advice on experimental interventions.
Social Media:
X: @sebastian_gero
LinkedIn: https://www.linkedin.com/in/sebastianlongbio/
Other Links/Mentions/Resources:
LongevityList.com: https://longevitylist.com/
Stranded Technologies Podcast interview: https://www.strandedtechnologies.com/p/ep-15-sebastian-a-brunemeier-on-the-9b0
ImmuneAgeBio: https://immuneage.bio/
Healthspan Capital: https://www.healthspancapital.vc/
Show Credits:
This episode was hosted by Anne Donohoe and Phil Carlson of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels:
X: @KCSAPodcastLabs
Instagram: @KCSAPodcastLabs
LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/
Petr Sramek, Investing in Longevity Tech
Tuesday, October 8, 2024 • Duration 55:22
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
Today, our hosts Phil Carlson and Anne Donohoe dive into the world of longevity technology with guest Petr Sramek, a visionary in the field of longevity tech. Petr is the co-founder, chairman, and managing general partner of the Longevitytech.fund, bringing over 33 years of experience as a serial tech entrepreneur. His impressive resume includes being a former entrepreneur-in-residence at Singularity University and co-founder of the Longevity Forum EU.
Currently serving on the boards of several cutting-edge companies in the longevity sector, including Animal Biosciences in the US and AgeCurve in the UK, Petr is dedicated to building the scientific, financial, and business infrastructure needed to accelerate the adoption of technologies that improve our health span.
Podcast Highlights:
Introduction of Petr Sramek (00:11): Overview of Petr's background as co-founder and chairman of the Longevity Tech Fund and his experience in technology entrepreneurship.
Concept of "Healthy Longevity" (02:48): Explanation of the focus on expanding the healthy and active part of life rather than just extending the overall lifespan.
Longevity Tech Fund Investment Strategy (17:35): Discussion of investment ticket sizes ranging from $100,000 to $600,000 and the fund's approach to selecting companies.
Longevity vs Traditional Biotech (29:34): Differentiation between longevity and traditional biotech investments, highlighting that aging is not classified as a disease.
CRISPR and Gene Therapy in Longevity (37:33): Examination of CRISPR's current limitations in longevity applications and the potential of gene therapy as a more relevant near-term approach.
Advice for Investors and Companies (42:54): Guidance for retail investors interested in the longevity space and information on how companies can pitch to the Longevity Tech Fund.
Personal Longevity Practices (47:30): Petr's sharing of his own experiences with longevity interventions, including his epigenetic age results showing a 16-year difference from his chronological age.
Guest's Social Media:
Petr’s LinkedIn: https://www.linkedin.com/in/petrsramek/
X: https://x.com/petrsramekbench
Other Links/Mentions/Resources:
Longevitytech.fund: https://www.longevitytech.fund/en/home
Longevity Forum EU: https://www.longevityforum.eu/en/home
HealthyLongevity.clinic: https://www.healthylongevity.clinic/
Singularity University: https://www.su.org/
AgeCurve: https://agecurve.co.uk/
Animal Bioscience: https://animalbioscience.com/about-us/
Show Credits:
This episode was hosted by Phil Carlson and Anne Donohoe of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels:
X: @KCSAPodcastLabs
Instagram: @KCSAPodcastLabs
LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/
Lou Reese, Next-Gen Vaccines
Tuesday, October 1, 2024 • Duration 55:33
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
Today, our host sat down with Lou Reese, co-founder and Vice Chairman of Vaxxinity, a purpose-driven biotechnology company pioneering a new class of medicines aimed at disrupting existing treatments for chronic diseases. Founded in 2014 alongside his wife and CEO, Mei Mei Hu, Vaxxinity is at the forefront of developing "next generation" vaccines for chronic conditions such as Alzheimer's, Parkinson's, heart disease, and migraine.
Lou Reese also serves on the Executive Committee of United Biomedical, Inc. (UBI), a multinational biopharmaceutical organization focused on developing diagnostics and immunotherapeutics for global health improvement. Lou was a director at ShenLian Biotech, one of the largest animal health companies in China, and co-founded an investment firm with ventures spanning real estate, energy, hospitality, and life sciences.
Podcast Highlights:
Introduction & Lou Reese's Background (3:00): Lou's journey and his mission to eliminate global suffering.
Synthetic Peptide Technology (10:15): Discussion of Vaxxinity's innovative approach to vaccine development.
Active Immunotherapy Medicines (18:30): Vaxxinity's work on developing active immunotherapy medicines.
Parkinson's Disease Breakthrough (23:45): Promising results from Vaxxinity's Parkinson's trials.
Company Restructuring (32:00): Vaxxinity's decision to delist and deregister, and plans for becoming a B Corp.
Army of Compassion (41:30): Global prevention trial for Alzheimer's and partnership with former Governor David Beasley.
Future of Healthcare (48:45): Lou's vision for affecting billions of lives and revolutionizing healthcare spending.
Social Media:
Lou Reese's LinkedIn: https://www.linkedin.com/in/lou-reese-6b54504/
X: https://x.com/notloureese
Other Links/Mentions/Resources:
Vaxxinity's official website: https://www.vaxxinity.com/
World Food Programme: https://www.wfp.org/
Mayo Clinic: https://www.mayoclinic.org/
UT Health: https://www.uthscsa.edu/
Amprion: https://www.amprionme.com/
United Therapeutics: https://www.unither.com/
Show Credits:
This episode was hosted by Lewis Goldberg of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing AltSpeaking@kcsa.com. You can also connect with us via our social channels:
X: @KCSAPodcastLabs
Instagram: @KCSAPodcastLabs
LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/
Dr. Bob Hariri, Evolution of Cellular Medicine
Tuesday, September 24, 2024 • Duration 44:10
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
We sat down with Dr. Bob Hariri, a renowned biomedical scientist, surgeon, and entrepreneur. He is the Founder, Chairman, and CEO of Celularity, a biotechnology company leading the next evolution in cellular medicine. Dr. Hariri pioneered the use of stem cells to treat a range of life-threatening human diseases and continues today to make transformative contributions in the fields of immuno-oncology and cell therapeutics along with tissue engineering and functional regeneration.
Dr. Hariri is widely acknowledged for his discovery of pluripotent stem cells derived from the human placenta, and as a member of the team that discovered the physiological activities of tumor necrosis factor (TNF). He holds over 150 issued and pending patents for discoveries including placenta-derived stem cells, which Nature recognized as one of the ten most important patent estates in the field. Dr. Hariri was the founder and CEO of Anthrogenesis Corporation, and after its acquisition by Celgene Corporation, served as CEO of Celgene Cellular Therapeutics. Dr. Hariri also co-founded the genomic-based health intelligence company, Human Longevity, Inc.
Podcast Highlights:
Introduction & Dr. Bob Hariri’s Research (1:00): Dr. Hariri's background and journey to longevity science.
Placental Stem Cells (04:30): Advantages of using placental-derived stem cells and their ethical considerations.
Universal Donor Tissue (10:05): Concept of the placenta as a universal donor tissue is explored, highlighting its potential in cellular therapies.
Genetic Modification (12:40): Process of gene modification in stem cells and their natural intelligence.
Chimerism (20:35): Potential therapeutic benefits of chimerism in cellular medicine.
Adult Stem Cell Banking (24:18): Cellularity's adult stem cell banking program and its value for future treatments.
Future of Stem Cell Medicine (36:40): A vision of stem cell medicine in 10 years, including potential treatments for cancer, autoimmune diseases, and aging-related conditions.
Other Links/Mentions/Resources:
Cellularity's official website: https://www.cellularity.com/
National Institutes of Health (NIH) information on stem cells: https://stemcells.nih.gov/
FDA resources: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products
Nature article on chimerism: https://www.nature.com/articles/d41586-021-01001-2
The American Society for Gene and Cell Therapy's patient education page: https://asgct.org/education
Social Media:
Dr. Hariri's Instagram: https://www.instagram.com/drbobhariri/?hl=en
Dr. Hariri's LinkedIn: https://www.linkedin.com/in/bob-hariri-md-phd-3654b239/
Show Credits:
This episode was hosted by Lewis Goldberg of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:
X: @KCSAPodcastLabs
Instagram: @KCSAPodcastLabs
LinkedIn: https://www.linkedin.com/company/kcsapodcastlabs/
Dr. Moshe Szyf, Epigenetics Pioneer
Tuesday, September 17, 2024 • Duration 47:30
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
Today, we sat down with Dr. Moshe Szyf, a pioneering figure in the field of epigenetics with a career spanning over three and a half decades. A founding figure in behavioral and psychiatric epigenetics, Dr. Szyf has authored over 300 influential papers that have significantly contributed to our understanding of how environmental factors and behaviors can influence gene expression without altering the DNA sequence itself.
Dr. Szyf serves as Chairman, CEO, and Chief Scientific Officer of HKG Epitherapeutics, focusing on developing epigenetic tools for clinical medicine, early disease detection, and personalized healthcare. He also currently holds the prestigious position of James McGill Professor of Pharmacology and Therapeutics at McGill University in Montreal, where he also holds the GlaxoSmithKline Chair in Pharmacology.
Dr. Szyf is a sought-after speaker, having presented at the Nobel Forum and delivered a TED talk on DNA and early life experiences. His work bridges academic research and practical applications, aiming to translate epigenetic insights into tangible health benefits for society.
Podcast Highlights:
Introduction to Epigenetics (00:11 - 02:37): Dr. Moshe Szyf is introduced as a pioneer in epigenetics. The concept of epigenetics is explained as the "software" that programs DNA, influencing how genes function without changing the DNA sequence itself.
HKG Epitherapeutics and Epigenetic Testing (02:38 - 06:05): Discussion of Dr. Szyf's company, HKG Epitherapeutics, which develops epigenetic tests for early disease detection, aging assessment, and health monitoring.
Epigenetics vs. Traditional Testing (06:06 - 09:44): Explanation of how epigenetic testing differs from traditional blood tests and genetic testing, offering insights into the dynamic changes happening at the DNA level.
Consumer Impact and Health Empowerment (09:45 - 14:42): Examples of how consumers have used epigenetic tests to gain insights into their biological age and health status, leading to lifestyle changes.
COVID-19's Impact on Healthcare Autonomy (29:38 - 33:40): Discussion on how the pandemic has led to increased public interest in personal health management and a shift towards more patient autonomy in healthcare decisions.
Future of Precision Medicine (39:12 - 42:06): Dr. Szyf's views on the role of epigenetics in precision medicine, particularly in guiding personalized drug treatments and lifestyle interventions.
Ethical Considerations and Balanced Approach to Longevity (34:55 - 39:11): Dr. Szyf's perspective on extreme anti-aging approaches, emphasizing the importance of balance and quality of life over extreme life extension methods.
Future Developments in Epigenetics (43:25 - 45:37): Discussion of anticipated breakthroughs in epigenetic technology, including improved accuracy in testing and applications for early detection of various chronic diseases.
Social Media:
LinkedIn https://www.linkedin.com/in/moshe-szyf-99ab283/?originalSubdomain=ca
@epimedtech https://twitter.com/epimedtech
Other Links/Mentions/Resources:
EpiMedTechGlobal https://epimedtech.com/
Dr. Szyf’s Ted Talk https://www.ted.com/talks/moshe_szyf_how_early_life_experience_is_written_into_dna?subtitle=en
CDC Resources for Epigenetics https://www.cdc.gov/genomics-and-health/about/epigenetic-impacts-on-health.html
Show Credits:
This episode was hosted by Anne Donohoe and Phil Carlson of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:
Dr. Nir Barzilai, Biology of Aging
Tuesday, September 10, 2024 • Duration 39:23
Welcome to Alternatively Speaking, a KCSA Podcast Labs production. In our debut season, we're diving into a revolutionary concept in health span, longevity, and healthcare.
Today, we sat down with Dr. Nir Barzilai, director of the Institute for Aging Research at the Albert Einstein College of Medicine and the Director of the Paul F. Glenn Center for the Biology of Human Aging Research and of the National Institutes of Health’s (NIH) Nathan Shock Centers of Excellence in the Basic Biology of Aging.
Dr. Barzilai discovered the first “longevity gene” in humans. His research established that the gene variant that leads to high HDL, or “good cholesterol,” is linked to healthy aging and extreme longevity. Dr. Barzilai has been profiled by major outlets, including The New York Times, PBS’ “NOVA scienceNow” and National Geographic.
Treatments for age-related diseases like type 2 diabetes are being developed based on Dr. Barzilai’s work and are currently in clinical trials. In addition to his “longevity gene” research, Dr. Barzilai studies key mechanisms involved in the biology of aging, including how nutrients and genetics influence lifespan. He is also investigating the physical and mental declines associated with aging and how they affect longevity. Dr. Barzilai is a professor of medicine (endocrinology) and of genetics, a member of the Diabetes Research Center, and director of the Diabetes Research and Training Center’s Animal Physiology core.
Podcast Highlights:
Introduction & Dr. Nir Barzilai’s Groundbreaking Discovery (00:00 - 03:15): Overview of Dr. Nir Barzilai’s discovery of the first “longevity gene” in humans and its link to healthy aging. Discussion on the significance of high HDL cholesterol and how it relates to extreme longevity.
The Science Behind Longevity Genes (03:16 - 08:32): Dive into the specific genetic markers that contribute to longevity. Dr. Barzilai shares insights on the mechanisms of aging and the potential to delay or reverse age-related diseases.
Current Clinical Trials on Age-Related Diseases (08:33 - 12:10): An exploration of the treatments for type 2 diabetes and other age-related conditions that are being developed from Dr. Barzilai’s research, with an update on the progress of these clinical trials.
Nutritional and Genetic Influence on Lifespan (12:11 - 17:48): How both genetics and nutrition shape our healthspan and longevity. Dr. Barzilai explains the latest findings on how diet can influence aging and the role of genetics in extending life.
Mental and Physical Decline in Aging (17:49 - 21:22): Discussion on the common declines in physical and mental health with aging, and how they impact longevity. Dr. Barzilai talks about ongoing research into mitigating these declines.
Future of Longevity Research (21:23 - 26:55): Dr. Barzilai shares his vision for the future of aging research, focusing on potential br
Social Media:
@NirBarzilaiMD: https://x.com/nirbarzilaimd?lang=en
https://www.linkedin.com/in/nir-barzilai-7a86a7212/
Other Links/Mentions/Resources:
Age Later by Nir Barzilai, M.D. https://us.macmillan.com/books/9781250230867/agelater
Albert Einstein College of Medicine https://einsteinmed.edu/faculty/484/nir-barzilai
American Federation for Aging Research (AFAR) https://www.afar.org/
Aging is a Treatable Condition - Worth.com
The 4 most promising anti-aging drugs investors are sleeping on, according to a leading longevity researcher - Business Insider
What is your Biological Age? - The New York Times
Show Credits:
This episode was hosted by Anne Donohoe and Phil Carlson of KCSA Strategic Communications.
Special thanks to our Program Director, Shea Gunther, and Executive Producer, Maria Petsanas.
You can learn more about how KCSA can help your cannabis and psychedelic companies by visiting www.kcsa.com or emailing greenrush@kcsa.com. You can also connect with us via our social channels:
Related Shows Based on Content Similarities
Discover shows related to Alternatively Speaking, based on actual content similarities. Explore podcasts with similar topics, themes, and formats, backed by real data.
